Overview

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Status:
Not yet recruiting
Trial end date:
2025-02-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein cholesterol (LDL-C) who are not on any lipid lowering therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals